A Phase III, Randomized, Open-Label, Multiple-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of Recombinant Human FSH of Cadila Healthcare Limited, India as compared to Gonal-F TM Administered Subcutaneously in Female Patients Undergoing Assisted Reproductive Technology.

Trial Profile

A Phase III, Randomized, Open-Label, Multiple-Dose, Parallel-Group Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity of Recombinant Human FSH of Cadila Healthcare Limited, India as compared to Gonal-F TM Administered Subcutaneously in Female Patients Undergoing Assisted Reproductive Technology.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Follitropin alfa (Primary)
  • Indications Female infertility
  • Focus Therapeutic Use
  • Sponsors Cadila Healthcare
  • Most Recent Events

    • 06 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 16 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top